We chose to evaluate BAL CRP in CF-ILDs, as there may be heterogeneity in the degree of inflammation and fibrosis in these subsets of ILD and could benefit from potential initiation/cessation of anti-inflammatory and/or antifibrotic therapy. Here, CRP is linked to interstitial lung disease.